<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01742598</url>
  </required_header>
  <id_info>
    <org_study_id>1106</org_study_id>
    <nct_id>NCT01742598</nct_id>
  </id_info>
  <brief_title>Assessment of St Jude Medical Portico Re-sheathable Transapical Aortic Valve System</brief_title>
  <acronym>Portico TA EU</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and performance of the 23mm Portico&#xD;
      Transcatheter Heart Valve and the TAVI Transapical Delivery System in subjects with severe&#xD;
      symptomatic aortic stenosis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event rates</measure>
    <time_frame>30 days</time_frame>
    <description>Cardiovascular mortality&#xD;
Myocardial Infarction (MI)&#xD;
Major Stroke&#xD;
Minor Stroke&#xD;
Acute Kidney Injury (AKI)&#xD;
Vascular access site and Access-related complications&#xD;
Bleeding&#xD;
Composite of periprocedural encephalopathy, all stroke, and all TIA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional improvements from baseline</measure>
    <time_frame>30 days</time_frame>
    <description>NYHA Functional Classification&#xD;
Six Minute Walk Test&#xD;
Effective Orifice Area (EOA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute device success</measure>
    <time_frame>At time of procedure</time_frame>
    <description>Successful apical access, delivery and deployment of the device and successful retrieval of the delivery system,&#xD;
Correct position of the device in the proper anatomical location,&#xD;
Intended performance of the prosthetic heart valve (Aortic Valve Area greater than (&gt;)1.0 cm2 and mean aortic valve gradient less than (&lt;) 20 mmHg or peak velocity less than (&lt;) 3 m/s, without moderate or severe prosthetic valve AR), and&#xD;
Only one valve implanted in the proper anatomical location</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Severe Symptomatic Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>Portico Implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Portico Transapical Aortic Valve System</intervention_name>
    <arm_group_label>Portico Implant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject has signed the study Informed Consent Form and Data Protection Form prior to&#xD;
             participating in the study.&#xD;
&#xD;
          2. Subject is 65 years of age or older at the time of index procedure, and/or has&#xD;
             comorbidities that, in the opinion of the Principal Investigator or the Subject&#xD;
             Selection Committee, preclude surgical valve replacement.&#xD;
&#xD;
          3. Subject's aortic annulus is 19-21mm diameter as measured by echocardiography (echo) or&#xD;
             CT conducted within 90 days prior to the index procedure.&#xD;
&#xD;
          4. Subject has senile degenerative aortic stenosis with echocardiography derived mean&#xD;
             gradient greater than (&gt;) 40mmHg or jet velocity greater than 4.0 m/s or an initial&#xD;
             valve area of less than (&lt;) 0.8 cm2 (or aortic valve area index less than or equal to&#xD;
             (≤) 0.6 cm2/m2). (Baseline measurement taken by echo within 90 days of index&#xD;
             procedure).&#xD;
&#xD;
          5. Subject has symptomatic aortic stenosis as demonstrated by NYHA Functional&#xD;
             Classification of II, III, or IV.&#xD;
&#xD;
          6. Subject is deemed high operable risk and suitable for TAVI per the medical opinion of&#xD;
             the Subject Selection Committee.&#xD;
&#xD;
          7. Subject's predicted operative mortality or serious, irreversible morbidity risk is&#xD;
             less than (&lt;) 50% at 30 days post index procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject is unwilling or unable to comply with all study-required follow-up&#xD;
             evaluations.&#xD;
&#xD;
          2. Subject has a documented history of a cerebral vascular accident (CVA) or transient&#xD;
             ischemic attack (TIA) within 6 months (less than or equal to (≤) 180 days) prior to&#xD;
             the index procedure.&#xD;
&#xD;
          3. Subject has a chest condition than prevents transapical access.&#xD;
&#xD;
          4. Subject has carotid artery disease requiring intervention.&#xD;
&#xD;
          5. Subject has documented evidence of a myocardial infarction (MI) within 6 months (less&#xD;
             than or equal to (≤) 180 days) prior to the index procedure.&#xD;
&#xD;
          6. Subject has a native aortic valve that is congenitally unicuspid, bicuspid,&#xD;
             quadricuspid or non-calcified as seen by echocardiography.&#xD;
&#xD;
          7. Subject has mitral valvular regurgitation greater than (&gt;) grade III.&#xD;
&#xD;
          8. Subject has moderate or severe mitral stenosis.&#xD;
&#xD;
          9. Subject has aortic root angulation greater than (&gt;) 70 degrees (horizontal aorta).&#xD;
&#xD;
         10. The distance from the left ventricular apex to the aortic annulus is less than (&lt;)&#xD;
             45mm (4.5cm).&#xD;
&#xD;
         11. Subject has a pre-existing prosthetic cardiac device, valve, or prosthetic ring in any&#xD;
             position.&#xD;
&#xD;
         12. Subject refuses any blood product transfusion.&#xD;
&#xD;
         13. Subject refuses surgical valve replacement.&#xD;
&#xD;
         14. Subject has left ventricular ejection fraction (LVEF) less than (&lt;) 20%.&#xD;
&#xD;
         15. Subject has documented, untreated symptomatic coronary artery disease (CAD) requiring&#xD;
             revascularization.&#xD;
&#xD;
         16. Subject has had a percutaneous interventional or other invasive cardiovascular or&#xD;
             peripheral vascular procedure less than or equal to (≤) 14 days of index procedure.&#xD;
&#xD;
         17. Subject has severe basal septal hypertrophy that would interfere with transcatheter&#xD;
             valve placement.&#xD;
&#xD;
         18. Subject has a history of, or is currently diagnosed with endocarditis.&#xD;
&#xD;
         19. Subject has imaging evidence of intracardiac mass, thrombus, or vegetation.&#xD;
&#xD;
         20. Subject is considered hemodynamically unstable (requiring inotropic support or&#xD;
             mechanical heart assistance).&#xD;
&#xD;
         21. Subject is in acute pulmonary edema or requiring intravenous diuretic therapy to&#xD;
             stabilize heart failure.&#xD;
&#xD;
         22. Subject with significant pulmonary disease as determined and documented by the&#xD;
             Investigator.&#xD;
&#xD;
         23. Subject has significant chronic steroid use as determined and documented by the&#xD;
             Investigator.&#xD;
&#xD;
         24. Subject has a documented hypersensitivity or contraindication to anticoagulant or&#xD;
             antiplatelet medication.&#xD;
&#xD;
         25. Subject has renal insufficiency as evidenced by a serum creatinine greater than (&gt;)&#xD;
             3.0 mg/dL (265.5µmol/L) or end-stage renal disease requiring chronic dialysis.&#xD;
&#xD;
         26. Subject has morbid obesity defined as a BMI greater than or equal to (≥) 40.&#xD;
&#xD;
         27. Subject has ongoing infection or sepsis.&#xD;
&#xD;
         28. Subject has blood dyscrasias (e.g., leukopenia, acute anemia, thrombocytopenia,&#xD;
             history of bleeding diathesis, or coagulopathy).&#xD;
&#xD;
         29. Subject has a current autoimmune disease that, in the opinion of the Principal&#xD;
             Investigator or the Subject Selection Committee, precludes the subject from study&#xD;
             participation.&#xD;
&#xD;
         30. Significant ascending aortic disease documented by diameter greater than 40mm.&#xD;
&#xD;
         31. Subject has an active peptic ulcer or has had gastrointestinal (GI) bleeding within 90&#xD;
             days prior to the index procedure.&#xD;
&#xD;
         32. Subject is currently participating in another investigational drug or device study.&#xD;
&#xD;
         33. Subject requires emergency surgery for any reason.&#xD;
&#xD;
         34. Subject has a life expectancy less than (&lt;) 12 months.&#xD;
&#xD;
         35. Subject has other medical, social or psychological conditions that, in the opinion of&#xD;
             the Principal Investigator or the Subject Selection Committee, preclude the subject&#xD;
             from study participation.&#xD;
&#xD;
         36. Subject is diagnosed with dementia or admitted to a chronic care facility which would&#xD;
             fundamentally complicate rehabilitation from the procedure or compliance with&#xD;
             follow-up visits.&#xD;
&#xD;
         37. Subject has a documented allergy to contrast media, nitinol alloys, porcine tissue, or&#xD;
             bovine tissue.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Walther, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kerckhoff Klinik</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>December 3, 2012</study_first_submitted>
  <study_first_submitted_qc>December 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2012</study_first_posted>
  <last_update_submitted>February 1, 2019</last_update_submitted>
  <last_update_submitted_qc>February 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TAVI</keyword>
  <keyword>TAVR</keyword>
  <keyword>aortic stenosis</keyword>
  <keyword>Transcatheter</keyword>
  <keyword>valvular heart disease</keyword>
  <keyword>aortic valve stenosis</keyword>
  <keyword>aortic valve replacement</keyword>
  <keyword>transcatheter aortic valve implantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

